Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Digital health: rise of the machines
Biotechnology
Digital health, which brings together digital and genetic data to improve healthcare, will play a vital role in personalised medicine. But there will be significant challenges when it comes to protecting this innovative new area. LSIPR looks at its uses and the potential challenges.   20 June 2014
Patent protection of amino acid and nucleic acid sequences
Americas
The rate of development in the biotech sector means revisions to the patent guidelines are more needed than ever, says Marisa Moura Momoli.   20 June 2014
Myriad woes for US innovators
Biotechnology
The USPTO’s new guidance for examiners extends the decision in Myriad beyond isolated nucleic acids to all claims concerning ‘judicial exceptions’. Bethan Hopewell and Jennifer Antcliff report.   20 June 2014
Asia-Pacific
China, Japan and South Korea are three of the most developed markets in the world for pharmaceuticals but they still offer a wealth of opportunities for both innovators and generic drug companies. LSIPR looks at the protection available for those seeking to do business there.   20 June 2014
Americas
Holland & Knight LLP has expanded its IP practice group with the hire of patent litigator Howard Suh as partner.   18 June 2014
Americas
Stem cell research companies in Canada and Australia have teamed up to support increased research and development in both countries.   16 June 2014
Americas
Drug giant Merck is to acquire biopharmaceutical company Idenix for $24.50 per share, valuing the purchase at around $3.85 billion.   12 June 2014
Generics
Irish-based drug manufacturer Actavis has settled its patent dispute with Zydus Pharmaceuticals.   10 June 2014
Big Pharma
Law firm Dechert LLP has appointed Rüdiger Herrmann as a partner in its Frankfurt office.   10 June 2014
Biotechnology
Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.   9 June 2014